查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589769

人工 T 細胞市場：按類型、應用和最終用戶分類 - 全球預測 2025-2030

Engineered T Cells Market by Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes), Application (Breast Cancer, Colorectal Cancer, Leukemia), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年人工T細胞市場價值為27.3億美元，預計2024年將達到34.3億美元，複合年成長率為25.72%，到2030年將達到135.6億美元。

工程化 T 細胞主要用於免疫療法，以修改患者的 T 細胞，以便更好地識別和攻擊癌細胞。此系列包括嵌合體抗原受體 (CAR) T 細胞療法和 T 細胞受體 (TCR) 療法。對工程化 T 細胞的需求源於提供標靶癌症治療的潛力，與傳統治療方法相比，副作用較少。它適用於各種血癌和一些固體癌。最終用途廣泛，包括醫院、研究機構和生技公司。基因編輯技術的進步、全球癌症發生率的增加以及私人和政府的大量投資推動了市場成長。主要商機在於開發現成的 T 細胞產品，以擴大在固體癌中的應用、改善安全性並提高可用性。然而，挑戰包括高昂的處理成本、複雜的製造流程和監管障礙。市場限制，例如嚴重的副作用、復發的可能性以及對基因改造的倫理擔憂也構成了障礙。用於精確基因編輯的 CRISPR-Cas9 創新、用於更好患者選擇的新型生物標記物的開發以及自動化製造流程是應對這些挑戰的關鍵。特別是，加深我們對腫瘤微環境的理解並解決癌細胞抗藥性機制的研究是有前景的。與製藥公司的合作、策略夥伴關係以及研發投資是業務成長的策略。此外，協調國際監管標準可以簡化核准和市場准入。整體而言，市場呈現出動態的特點，其特點是科學的快速進步和監管環境的變化。對研發的策略性投資以及對擴大治療適應症的關注可以帶來巨大的回報。如果持續存在的挑戰得到妥善解決，就有充分的機會發展出具有更高功效和安全性的治療方法。

主要市場統計
基準年[2023] 27.3億美元
預測年份 [2024] 34.3億美元
預測年份 [2030] 135.6億美元
複合年成長率（%） 25.72%

市場動態：揭示快速發展的人工 T 細胞市場的關鍵市場洞察

供需的動態交互作用正在改變工程 T 細胞市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症盛行率上升
    • 對創新生物製藥治療的需求不斷增加
    • CAR-T細胞工程的最新進展
  • 市場限制因素
    • 人工 T 細胞療法相關的高成本
  • 市場機會
    • 研發經費推動免疫腫瘤學領域蓬勃發展
    • 基因治療市場的擴大
  • 市場挑戰
    • 人工 T 細胞的安全問題與可能的副作用

波特五力：駕馭人工 T 細胞市場的策略工具

波特的五力框架是了解人工 T 細胞市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解人工 T 細胞市場的外部影響

外部宏觀環境因素在塑造人工 T 細胞市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解人工T細胞市場的競爭狀況

人工 T 細胞市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣人工 T 細胞市場供應商的績效評估

FPNV定位矩陣是評估工程T細胞市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製人工 T 細胞市場的成功之路

對於想要加強在全球市場的影響力的公司來說，對人工 T 細胞市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率上升
      • 創新生物製藥療法的需求不斷增加
      • CAR-T細胞工程的最新進展
    • 抑制因素
      • 工程 T 細胞療法相關的高成本
    • 機會
      • 研發經費投入推動免疫腫瘤學領域蓬勃發展
      • 基因治療市場的擴大
    • 任務
      • 人工 T 細胞的安全問題與可能的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 人工 T 細胞市場：依類型

  • 嵌合體抗原受體
  • T細胞受體
  • 腫瘤浸潤淋巴細胞

第 7 章 人工 T 細胞市場：依應用分類

  • 乳癌
  • 大腸直腸癌
  • 白血病
  • 肺癌
  • 惡性黑色素瘤

第 8 章 人工 T 細胞市場：依最終用戶分類

  • 癌症研究中心
  • 診所
  • 醫院

第9章美洲人工T細胞市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太人工T細胞市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲人工T細胞市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Autolus
  • Bellicum Pharmaceuticals, Inc.
  • Bristol Myers Squibb
  • Cabaletta Bio, Inc.
  • ElevateBio, LLC
  • Elli Lilly and Company
  • Gilead
  • Kuur Therapeutics by Athenex
  • Novartis AG
  • Oxford BioMedica
  • Pfizer Inc.
  • Precision Biosciences
  • Tmunity Therapeutics Inc.
  • TScan Therapeutics, Inc.
Product Code: MRR-4348D129FAA9

The Engineered T Cells Market was valued at USD 2.73 billion in 2023, expected to reach USD 3.43 billion in 2024, and is projected to grow at a CAGR of 25.72%, to USD 13.56 billion by 2030.

Engineered T cells, primarily used in immunotherapy, involve modifying patients' T cells to better recognize and attack cancer cells. This scope includes Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell Receptor (TCR) therapy. The necessity of engineered T cells arises from their potential to provide targeted cancer treatments with reduced side effects compared to traditional therapies. Applications extend to various hematologic cancers and some solid tumors. End-use scopes span hospitals, research institutes, and biotechnology companies. Market growth is propelled by advancements in gene-editing technologies, increasing incidences of cancer worldwide, and substantial private and governmental investments. Key opportunities lie in expanding applications in solid tumors, improving safety profiles, and developing off-the-shelf T cell products to enhance accessibility. However, challenges include high treatment costs, complex manufacturing processes, and regulatory hurdles. Market limitations such as severe side effects, potential relapse cases, and ethical concerns regarding genetic modifications also present hurdles. To combat these challenges, innovations in CRISPR-Cas9 for precise gene editing, developing novel biomarkers for better patient selection, and automated manufacturing processes are critical. Research is particularly promising in enhancing tumor microenvironment understanding and tackling cancer cell resistance mechanisms. Pharmaceutical collaborations, strategic partnerships, and investments in R&D are strategies for business growth. Additionally, harmonizing international regulatory standards can streamline approvals and market access. Overall, the market displays a dynamic nature, characterized by rapid scientific advancements and shifting regulatory landscapes. Strategic investments in R&D, coupled with a focus on expanding therapeutic indications, could yield significant dividends. Opportunities are ripe for exploitation in developing therapies with improved efficacy and safety profiles, provided that ongoing challenges are adeptly managed.

KEY MARKET STATISTICS
Base Year [2023] USD 2.73 billion
Estimated Year [2024] USD 3.43 billion
Forecast Year [2030] USD 13.56 billion
CAGR (%) 25.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Engineered T Cells Market

The Engineered T Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in prevalence of cancer diseases
    • Increasing demand for innovative biopharmaceutical therapies
    • Recent advances in CAR-T cell engineering
  • Market Restraints
    • High cost associated to engineered T cells treatment
  • Market Opportunities
    • Immuno-oncology sector booming with R&D funding
    • Expanding gene therapy marketspace
  • Market Challenges
    • Safety issues and possible side-effects with engineered T cells

Porter's Five Forces: A Strategic Tool for Navigating the Engineered T Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Engineered T Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Engineered T Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Engineered T Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Engineered T Cells Market

A detailed market share analysis in the Engineered T Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Engineered T Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Engineered T Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Engineered T Cells Market

A strategic analysis of the Engineered T Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Engineered T Cells Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Autolus, Bellicum Pharmaceuticals, Inc., Bristol Myers Squibb, Cabaletta Bio, Inc., ElevateBio, LLC, Elli Lilly and Company, Gilead, Kuur Therapeutics by Athenex, Novartis AG, Oxford BioMedica, Pfizer Inc., Precision Biosciences, Tmunity Therapeutics Inc., and TScan Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Engineered T Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chimeric Antigen Receptor, T Cell Receptor, and Tumor-Infiltrating Lymphocytes.
  • Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Melanoma.
  • Based on End-User, market is studied across Cancer Research Centers, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in prevalence of cancer diseases
      • 5.1.1.2. Increasing demand for innovative biopharmaceutical therapies
      • 5.1.1.3. Recent advances in CAR-T cell engineering
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated to engineered T cells treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Immuno-oncology sector booming with R&D funding
      • 5.1.3.2. Expanding gene therapy marketspace
    • 5.1.4. Challenges
      • 5.1.4.1. Safety issues and possible side-effects with engineered T cells
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Engineered T Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric Antigen Receptor
  • 6.3. T Cell Receptor
  • 6.4. Tumor-Infiltrating Lymphocytes

7. Engineered T Cells Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Leukemia
  • 7.5. Lung Cancer
  • 7.6. Melanoma

8. Engineered T Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Centers
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Engineered T Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Engineered T Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Engineered T Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Autolus
  • 3. Bellicum Pharmaceuticals, Inc.
  • 4. Bristol Myers Squibb
  • 5. Cabaletta Bio, Inc.
  • 6. ElevateBio, LLC
  • 7. Elli Lilly and Company
  • 8. Gilead
  • 9. Kuur Therapeutics by Athenex
  • 10. Novartis AG
  • 11. Oxford BioMedica
  • 12. Pfizer Inc.
  • 13. Precision Biosciences
  • 14. Tmunity Therapeutics Inc.
  • 15. TScan Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ENGINEERED T CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. ENGINEERED T CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENGINEERED T CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENGINEERED T CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY T CELL RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023